ArticlePloS one2025
Construction of a prognostic prediction model for concurrent radiotherapy in cervical cancer using GEO and TCGA databases with preliminary validation analysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FABP4/5-Mediated Lipid Reprogramming Is Associated with Immunosuppressive T Cell Crosstalk in Cervical Cancer After Chemoradiotherapy.Biomedicines · 2026Article
- Integrated Network Pharmacology and Molecular Dynamics Reveal Luteolin fromInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiotherapy is a primary treatment for intermediate and advanced cervical cancer (CC). Resistance to radiotherapy is a principal reason for treatment failure in synchronous applications, yet the molecular mechanisms remain poorly understood. Identifying reliable prognostic markers to predict and evaluate patient outcomes is essential for advancing therapeutic strategies. This study aims to address this need by developing a prognostic prediction model for concurrent radiotherapy in CC, utilizing both single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data.
methodsThe research began by screening for co-expressed genes using samples from two GEO datasets (GSE236738 and GSE56363). To pinpoint target genes that exhibit significant co-expression, both univariate and multivariate Cox regression analyses were conducted, facilitating the development of prognostic prediction models. The clinical significance of these models was confirmed through the analysis of 144 CC samples sourced from the TCGA database, utilizing Kaplan-Meier survival curves, ROC curve analyses, and Spearman's correlation tests to investigate the relationships between gene expression and the levels of immune cell infiltration. IHC assays were conducted to further validate the prognostic potential of the identified target genes in CC patients.
resultsPrognostic models for four target genes-MPP5, SNX7, LSM12, and GALNT3-showed significant predictive value for the outcomes of CC patients undergoing radiotherapy, as demonstrated using the GSE236738 and GSE56363 datasets. The prognostic efficacy of the model was illustrated through scatter plots and calibration curves. Additionally, the model exhibited significant associations with tumor immune infiltration, immune checkpoints, and chemotherapeutic drug sensitivity. Immunohistochemistry (IHC) on clinical tumor samples confirmed that the protein expression levels of MPP5, SNX7, LSM12, and GALNT3 were distinctively predictive for CC patients.
conclusionThe results indicate that MPP5, SNX7, LSM12, and GALNT3 are significantly associated with radiotherapy sensitivity in CC cells. A prognostic risk model based on these genes demonstrated strong predictive capabilities for patient outcomes in radiotherapy, suggesting these genes as effective predictors and potential therapeutic targets for treating CC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.